Background: Patients with severe depletion of skeletal muscle (sarcopenia) are prone to dose-limiting toxicity (DLT) during fluoropyrimidine therapy. We hypothesized that sarcopenia may also predict toxicity of targeted therapy drugs. Weight, height and skeletal muscle cross-sectional area at the third lumbar vertebra were measured by computed tomography (CT). Toxicity was assessed.
introduction
Sorafenib is a multikinase inhibitor whose therapeutic action involves inhibiting tumor cell proliferation and tumor angiogenesis. In renal cell cancer (RCC) patients compared with placebo, sorafenib treatment at a flat dose of 800 mg (400 mg b.i.d.) increased progression-free survival by 2.7 months [1] . Sorafenib's common toxic effects are cutaneous (hand-foot syndrome, rash) and gastrointestinal (GI; diarrhea, nausea) as well as alopecia and fatigue. These toxic effects limit patient's ability to receive full-dose sorafenib treatment and account for dose reductions in 13% and treatment termination in 21% of patients [1] .
The majority of anticancer drugs have a narrow therapeutic index, and it is important to determine factors that explain individual variation in efficacy and toxicity. Our recent work has focused on body composition as a potential determinant of toxicity in response to commonly used antineoplastic agents.
Proportions of skeletal muscle (and overall lean tissue) in the body appear pertinent, as several recent results demonstrate an association between severe skeletal muscle depletion (sarcopenia) and excess toxicity during treatment with fluoropyrimidines even when these drugs were given in a manner adjusted to body surface area (BSA) [2] . Sarcopenia is generally defined as an absolute muscle mass below the fifth percentile for healthy adults. Sarcopenia has also been related to poor functional status and reduced overall survival in patients with solid tumors [3] .
Relationships between body composition and the toxicity of targeted therapies have not yet been studied, and here, we undertook to determine if features of body composition may be predictive of dose-limiting toxicity (DLT) in patients treated with sorafenib. Sorafenib is applied at a constant dose of 800 mg/day, without adjustment for body weight. Renal cell carcinoma patients have strikingly heterogeneous weight and body mass index (BMI; 15.2-38.1 kg/m 2 ) [4] and thus, body size could be a potential source of variation in drug concentration and metabolism. There are a few results indicating a link between low BMI and toxicity for some cytotoxic chemotherapy [5] as well as some targeted therapies [6] .
Here, we analyzed a sample of patients of the TARGET trial (treatment approaches in renal cancer global evaluation trial) [1] , a phase III study of sorafenib versus placebo for RCC. Our objective was to test for relationships between BMI and muscle mass and the presence of DLT, defined here as toxicity leading to dose reduction (to 400 mg/day) or to termination of treatment.
materials and methods patients
Participants in the TARGET trial treated at the Institut Gustave Roussy (Villejuif, France) were evaluated. Subjects were part of a phase III, placebocontrolled, multicentre trial and were stratified by country and Memorial Sloan Kettering Cancer Center prognostic score. For the original phase III study, all patients provided informed consent; the study was approved by local research ethics boards in participating centers according to good clinical practice and applicable laws. Further analysis of clinical toxicity data and interpretation of body composition from computed tomography (CT) images was approved by the local ethics board.
study design
Full details of the study are described elsewhere [1] . Briefly, after stratification, and randomization, patients were treated in a double-blind fashion with sorafenib 400 mg b.i.d. or placebo. Sorafenib was reduced to 400 mg daily in the case of severe toxicity defined using V3.0 of the Common Terminology Criteria for Adverse Events. If toxicity was not thereby resolved, treatment was terminated and if so, patients were returned to the initially scheduled dose. Treatment was not unblinded except in the case of radiologically proven disease progression; however, after an interim analysis showed a progression-free survival advantage with sorafenib, placebo-treated patients with disease progression were permitted to cross over to the sorafenib arm.
anthropometry and body composition
Weight and height had been recorded during clinic visits according to standard methods. Weight was measured using a medical balance beam scale with subjects barefoot and wearing a hospital gown. Height was measured with a stadiometer without shoes. BMI (kg/m 2 ) was calculated and the World Health Organization (WHO) categories were used: underweight, BMI < 18.5; normal, 18.5 < BMI < 24.9; overweight 25 < BMI < 29.9; obese BMI > 30.
CT has proven accurate for measuring body composition [7, 8] . Regional adipose tissues (visceral and s.c.) and muscle tissues were assessed on CT images in the patient record, which had been done for diagnostic and follow-up purposes. Images closest to the start of sorafenib treatment were considered (on average 16.8 6 28.3 days from the start of treatment). The third lumbar vertebra (L3) was chosen as a landmark, and two consecutive slices were assessed to measure cross-sectional area of muscle and adipose tissue as described [3, 9] . The average value of two images was computed for each patient. Images were analyzed using Slice-O-Matic software V4.3 (Tomovision). Cross-sectional areas (cm 2 ) of respective tissues were computed for each image. Directly measured body composition variables assessed here, total lumbar skeletal muscle cross-sectional area (cm 2 ) and total lumbar adipose tissue area (cm 2 ), are linearly related to whole-body muscle and adipose tissue mass [9, 10] . As in our other work, these values are normalized for stature as is conventional for BMI and body composition components [3, 9] and expressed in units of cm Eighty-four patients were identified. The placebo group initially included 41 patients and for 14 of these, the amendment of the protocol after the interim analysis permitted crossover to the sorafenib arm. Of 43 patients initially randomly assigned to receive sorafenib, 2 lacked evaluable CT images. A total of 55 patients were included in the analysis presented here, 41 who were initially randomized to sorafenib and 14 who were crossed over to sorafenib (Table 1) . Anthropometric and body composition features were variable, with coefficients of variation, respectively, for weight, BMI, lumbar skeletal muscle index and lumbar adipose tissue index of 22.6%, 16.4%, 18.8% and 51.9%. Sex was an important determinant of the overall variation and female and male participants differed with respect to all anthropometric and body composition characteristics evaluated (Table 1 ). Very few patients would be considered clinically underweight by WHO standards (n = 4, all women). By contrast, just over half (50.9%) started the study overweight or obese (Table 1) . Sarcopenia was present in more than half of the patients overall (54.5%) and in 40% of the overweight or obese patients.
sorafenib toxicity
Twelve patients (21.8%) experienced a DLT, 22.6% of males and 22% of females. For eight patients, the dose was reduced to 400 mg daily and treatment was stopped in four patients. DLT included two instances of grade IV toxicity (abdominal pain, rash) and three instances of grade III diarrhea. In the remaining cases, patients had multiple (two, three or four simultaneous) toxic effects of grade II, with hand-foot syndrome, rash and diarrhea being the most common.
We analyzed the toxicity data in function of both BMI and L3 skeletal muscle index, on the basis of the idea that at a flat dose of 800 mg, people with smaller body weight would have a higher dose per unit body weight and also that sarcopenia may be a risk factor for toxicity. All patients considered, the mean BMI of patients with DLT was significantly lower than in those who were able to continue at 800 mg sorafenib/day (23.1 versus 26.0 kg/m 2 ; P < 0.03) ( Table 2) . This difference was especially prominent in males, of which those with DLT were on average 3.3 units of BMI lighter than those without (P < 0.02). Males with DLT had significantly less skeletal muscle than those without DLT (Table 2) , and all but one of these met criteria for sarcopenia. Considering sarcopenia per se, 37% (7 of 19) of males who were sarcopenic experienced DLT; only 5% (1 of 18) of males who were not sarcopenic had a DLT (P < 0.04). Figure 1 illustrates the distribution of BMI, muscle index and DLT for men treated with sorafenib. Males who were simultaneously below BMI 25 and sarcopenic (i.e. in the lower left quadrant of Figure 1 ) (5 of 7, 71%) experienced DLT, while only 3 of 30 (10%) of the remaining males had DLT (P < 0.01). Conversely, very few patients with BMI > 25 kg/m 2 and/or high muscle index experienced severe toxicity. Only 1 of 18 male patients whose muscle index was above the cut-off for sarcopenia (5.5%) and only 3 of 28 male patients whose BMI was >25 (11%) experienced a DLT.
The number of female patient was too small (n = 18 in total) to analyze by quadrants as for the males; however, when patients for both sexes were combined, those with low BMI and sarcopenia (n = 17) had a higher probability of DLT (41%) as opposed to patients outside this quadrant (5 of 38; 13%; P = 0.03).
discussion
While a relatively small number of patients were available for this analysis, we evaluated a sample from a single cancer center that participated in a larger clinical trial conducted under rigorous conditions. Our findings point to body composition as a potentially important source of variation in the toxicity of a targeted therapy and to the need for investigations of a larger scale. On the basis of these results, we indicate that flat dosing of sorafenib (800 mg) across a wide range of BMI (17.2-38.7 kg/m 2 ) and relative original article Annals of Oncology muscularity may not appropriately adjust to variations in the physiognomy of RCC patients. It would seem logical to take into account weight, or some derivative of weight such as BMI, for molecules with a narrow therapeutic index. Some available results indicate the potential importance of adapting doses of cytotoxic chemotherapy to BMI. The study of Miya et al. [11] indicated that BMI may be a factor related to toxicity even in patients given drugs adjusted to BSA; in a multivariate analysis, BMI and sex were the two elements significantly associated with C max of CPT-11 administered at 100 mg/m 2 . BMI was inversely related to the fall in leukocyte and platelet counts during treatment with cisplatin and etoposide [12] . BMI < 20 kg/m 2 was associated with diarrhea during radiochemotherapy of rectal cancer [5] . Very few data are available regarding BMI and targeted therapies; however, the study of Telli et al. [6] raised concerns about flat dosing. Of 45 patients treated with sunitinib (the majority for metastatic renal cancers), 7 developed grade III/IV cardiotoxicity; the mean BMI of these patients (23.9 kg/m 2 ) was considerably less than patients who experienced no cardiotoxicity (BMI = 27.1 kg/m 2 ; P = 0.03). Muscle mass is another parameter which is emerging as important in relation to outcomes of cancer [3] and anticancer therapy [2] . Body weight trends in westernized societies and higher incidence of certain cancers in obese individuals [13] result in a high proportion of cancer patients presenting as overweight or obese (here 67.6% of men and 50.1% of the patients overall). These high weights obscure a loss of muscle mass, and if one employs cut points validated in the literature [3] , 30 of 55 (54%) patients in our study were sarcopenic, while only 4 (7%) would be considered clinically underweight by accepted criteria (BMI < 18.5). Sarcopenia has important prognostic significance for obese patients with solid tumors of the lung or GI tract, with a difference of 10 months in median survival of sarcopenic obese patients compared with obese patients without sarcopenia [3] . Relationships between muscularity and treatment toxicity are emerging from recent studies. In colon cancer patients treated with 5-fluorouracil (5-FU), Prado et al. [2] showed an increase in DLT in patients with low muscle mass. Aslani et al. [14] showed that low body protein mass predicted hematologic toxicity in women with breast cancer treated with 5-FU. Recently, we obtained further evidence that sarcopenia associates with DLT in breast cancer patients treated with either capecitabine [15] or epirubicin (Prado et al., unpublished data). All these results point to the importance of muscle mass independent of weight or of BMI.
Several mechanisms of increased toxicity in patients with sarcopenia may be hypothesized. Altered body composition may relate to alterations in the distribution, metabolism and clearance of antineoplastic agents; this remains to be tested. Sarcopenic patients have also been characterized to be prone to a variety of insults and stressors, including increased propensity for nosocomial infections and other complications in hospital [16] . Increased toxicity in response to fluoropyrimidines [14, 15] as well as sorafenib may be additional manifestations of a generalized intolerance. Finally, sarcopenia and treatment toxicity may potentially be linked by systemic inflammation, which is indicated to underlie both these conditions [17] . 
